Ibuprofen (300 mg/kg; p.o.; daily, for 14 days) L-lysine reduces overall tumor growth and enhances anti-tumor immune characteristics without adverse autoimmune reactions in a model of postpartum breast cancer[5].
Ibuprofen (60 mg/kg; i.h.; every second day for 15 days) L-lysine reduces the risk of neuropathy in a rat model of chronic Oxaliplatin induced peripheral neuropathy[6].
Ibuprofen (20 mg/kg; p.o.; every 12 hours, 5 doses total) L-lysine decreases muscle growth (average muscle fiber cross-sectional area) without affecting regulation of supraspinatus tendon adaptions to exercise[7].
Ibuprofen (35 mg/kg; p.o.; twice daily) L-lysine attenuates the Inflammatory response to pseudomonas aeruginosa in a rat model of chronic pulmonary infection[8].
| Animal Model: | Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum)[5] |
| Dosage: | 300 mg/kg, daily for 14 days |
| Administration: | Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly) |
| Result: | Suppresed tumor growth, reduced presence of immature monocytes and increased numbers of T cells.
Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.
|
| Animal Model: | Oxaliplatininduced peripheral neuropathy[6] |
| Dosage: | 60 mg/kg, every second day for 15 days |
| Administration: | Subcutaneous injection |
| Result: | Lowered sensory nerve conduction velocity (SNCV). |
